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Patients with cerebral palsy, spinal cord injuries, trau-
matic brain injuries and multiple sclerosis may suffer
from intractable spasticity and rigidity that can lead
to significant disability. Muscle tightness and invol-
untary movements of the limbs and body owing to
spasticity in such patients can greatly impact their
mobility, care, sleep and ability to transfer. Baclofen is
an effective oral antispasmodic therapy for most
patients [1–3], but treatment may not be successful in
a significant number of patients owing to the severity
of their symptoms or the presence of unacceptable
side effects. In such situations, intrathecal delivery of
baclofen via an implanted infusion pump allows for
a more potent antispasmodic effect and fewer side
effects. Promising results in the control of spasticity
and rigidity have been reported in the medical litera-
ture [4–12], but a variety of mechanical and surgical
complications have been recognized. The catheter
sits in the lumbar subarachnoid space and is the most
vulnerable part of the electromechanical infusion
system [13]. Previous studies have noted that these
catheters are prone to dislodgment, kinking, tearing
and disconnection in as many as 40% of the patients
who have used these systems [7–9,14,15]. It may be
difficult to detect if and when the catheter tip migrates
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We report a case of intrathecal baclofen infusion pump implantation complicated by migration of
the catheter tip. A 55-year-old man required an intrathecal baclofen infusion for severe spasticity
4 years after a cervical spinal cord injury with incomplete tetraparesis. Twelve months after initial
implantation of the device, the patient began to experience a recurrence of trunk tightness and
spasticity. Subsequent X-ray and computed tomography evaluations of the catheter system revealed
pooling of contrast medium outside of the intrathecal distribution in the lumbar subcutaneous
region of the back and therefore migration of the pump catheter tip. At surgical revision, emphasis
was placed on minimizing the length of catheter outside of the spine and securing the catheter in
the supraspinous fascia with a right-angled anchor. The distance between the anchors and the entry
point of the catheter into the supraspinous fascia was also reduced to prevent slipping when the
patient bends forward. After surgery, the patient’s spasticity improved and, 1 year later, he has
experienced no further complications during follow-up, requiring an average baclofen dose of
150μg/day. Here, we describe several surgical methods intended to secure the intrathecal catheter
and prevent catheter migration. Other complications related to catheter failure are also highlighted.
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from its original position. Here, we describe a patient
who suffered increasingly severe spasticity owing to
migration of the catheter tip outside of the intrathecal
space 12 months after the initially successful implan-
tation and intrathecal therapy.
CASE PRESENTATION
A 55-year-old man had previously suffered a trau-
matic cervical spinal injury resulting in incomplete
tetraparesis and was originally treated with anterior
discectomy and fusion followed by decompressive
cervical laminoplasty. The patient initially recovered
with improvements in muscle power in both the upper
and lower limbs and was able to walk again a few
weeks after the surgical intervention. However, he
gradually developed increasing spasticity of the trunk
and extremities (especially the lower limbs) despite
titration of his oral baclofen dose from 15 mg/day to
60 mg/day. He suffered from severe spasms and trunk
tightness that limited his daily activities and induced
intolerable pain. For these reasons, some 4 years after
his initial injury, it was deemed that oral therapy was
insufficient and he agreed to a test dose of intrathecal
baclofen. This proved to be very effective at a dose of
75μg, and his Ashworth score was reduced from 4/5
to 2/5. An intrathecal infusion pump was surgically
implanted (SynchroMed; Medtronic, Minneapolis,
MN, USA) with the patient in a lateral position,
allowing access to the abdomen for the placement of
the pump and to the spine for catheter placement. 
A paramedian skin incision was made over the lum-
bar spine down to the supraspinous fascia. A 15-gauge
needle was advanced in a cephalad direction until
free flow of the cerebrospinal fluid was obtained, and
the catheter was then passed meticulously through the
needle. The catheter tip was positioned at the level of
T12, and this was confirmed with fluoroscopy. A tun-
nel rod was used to tunnel the catheter to the abdo-
men where it was connected to the pump that was
placed in a subcutaneous location.
During the first 3 months after surgery, spasticity
was controlled with an average daily dose of 180μg
of intrathecal baclofen and his Ashworth score re-
mained at 2/5. However, 12 months after surgery, the
patient experienced increasing trunk tightness and
spasticity, and his rehabilitation physician increased
the baclofen dose from 180μg/day to 300μg/day.
Although withdrawal symptoms were not evident,
the patient found that transfers and sitting were be-
coming increasingly difficult.
Upon hospitalization, the intrathecal infusion
pump function and programming appeared satisfac-
tory. When radio-opaque solution was injected into
the side port of the pump, X-ray evaluation demon-
strated that the contrast medium was accumulating
within the lumbar paraspinal region and not in the
subarachnoid space (Figure 1A). Computed tomogra-
phy further revealed the accumulation of the contrast
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Figure 1. (A) X-ray evaluation of the catheter system with contrast medium accumulating outside of the intrathecal distribution in
the lumbar paraspinal region (black arrows). The syringe used to introduce the contrast via the side port of the pump is indicated (white
arrow). (B) Computed tomography further demonstrates the accumulation of contrast medium in the subcutaneous layers (white arrow).
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medium in the subcutaneous layers (Figure 1B) and,
as a result, surgery was planned to adjust the posi-
tioning of the catheter tip.
During the operation, the catheter was found to
be coiled in a subcutaneous pocket outside of its ini-
tial intradural position and was removed (Figure 2B).
A new catheter was inserted into the intrathecal posi-
tion. The new catheter was trimmed to an optimal
length to prevent collecting in the lumbar paraspinal
region and emphasis was placed on minimizing the
length of catheter outside of the spine. The catheter
was secured in the supraspinous fascia with an addi-
tional right-angled anchor (Figures 2C and 2D). The
distance between these anchors and the point of
entry of the catheter into the supraspinous fascia was
also minimized to prevent the catheter from slipping
when the patient bends over (Figure 2D). The new
catheter was connected to the infusion pump and the
wound was closed in layers in the normal way.
After surgery, the dose of intrathecal baclofen was
resumed at 195μg/day and his symptoms gradually
improved. Postoperative X-ray confirmed that the
catheter tip was in a good position at the lower tho-
racic level. At 1 year after surgical revision, there have
been no further complications and he remains on an
average baclofen dose of 150μg/day.
DISCUSSION
The intrathecal baclofen pump is a device designed
to deliver small doses of baclofen into the subarach-
noid space. Although this treatment modality can be
very effective in the relief of intractable spasticity and
pain, it is not without complications. In broad terms,
complications can be divided into those related to the
surgical implantation or mechanical functioning of the
infusion device and those related to the drug itself.
A B
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Figure 2. (A) During the first operation, a single straight anchor was used to secure the catheter in the subcutaneous layer. (B) At sur-
gical revision, the catheter was found to be coiled outside of the intradural position in a subcutaneous pocket. (C) A right-angled anchor
was subsequently used to secure the catheter in the supraspinous fascia. (D) The right-angled and straight anchors were positioned to
minimize catheter migration.
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With respect to the function of the infusion device,
the most vulnerable part of the system is the catheter.
Albright et al [16] and Tutak and Doleys [17] reported
that the incidence of complications relating to the
catheter itself may be as high as 31% and 35%, respec-
tively. Of these catheter-related complications, over
50% were attributed to kinking, breakage or tearing of
the thin silastic catheter [13], and disconnections and
dislodgments of the catheter were far less common
problems. It seems simple to make a more solid and,
therefore, durable single connection between the
catheter and pump to prevent potential disconnec-
tions in the catheter system with multiple connection
points. However, it is more difficult to prevent dis-
lodgment of the catheter tip from the subarachnoid
space, and this migration is exacerbated by repetitive
pulling movements on the catheter as the patient
moves. It has been suggested that the differential
motion generated during spastic ambulation between
the pump located in the abdomen and the spine may
contribute to the gradual withdrawal of the catheter
[18]. Specific steps can be taken during the surgical
implantation of the device to limit occurrence of
these complications described thus far. First, given
that the intrathecal catheter is more prone to kinking
and fracture, the length of catheter outside the spine
should be minimized. A right-angled anchor should
be used to secure the catheter in the correct position
and prevent redundant catheter from migrating. The
anchor should be secured to the supraspinous fascia
so that it prevents gliding of the catheter when the
patient bends over. In our case, it should be noted
that only one straight anchor was initially used to
secure the catheter in the subcutaneous tissue, and
the redundant catheter collected between this and
the entry point into the spine (Figure 2A). These fac-
tors certainly contributed to the unwanted migration
of the catheter and, hence, during the second opera-
tion, these issues were addressed (Figures 2C and 2D).
The distance between the straight and right-angled
anchors and the entry point of the catheter into the
supraspinous fascia were minimized to prevent the
catheter from slipping out when the patient bent over
(Figure 2D), but excessive tension should not be
applied whilst securing the anchor in this fashion so
that the catheter does not snap back under strain. 
A permanent braided suture was used because it 
is stronger and easier to place. In addition, excess
tubing was coiled around and beneath the pump to
provide some slack between the pump and spine
during movement.
Baclofen withdrawal syndrome is a potentially life-
threatening condition and complication of intrathecal
baclofen injection (and a failure thereof). The most
common symptoms include hyperthermia, itching and
hypertonicity, but multiorgan failure, rhabdomyolysis,
severe hyperthermia, neuroleptic malignant syndrome
and seizure have also been noted. Acute withdrawal
most commonly occurs after pump failure when ad-
ministering intrathecal doses, and immediate admin-
istration of a supplementary oral or intrathecal bolus
of baclofen would be needed. Our patient did not
present with symptoms of acute baclofen withdrawal,
and we suspect that this was because the gradual mi-
gration of the catheter created a relatively gradual
decrease in intrathecal baclofen concentrations rather
than an abrupt change. However, it is important that
the drug delivery system is regularly checked by a
specialist and/or trained caregiver so that the inci-
dence of life-threatening intrathecal baclofen with-
drawal syndrome is kept as low as possible. It can be
very difficult to diagnose malfunctions in the pump
system, even in specialist centers. The clinician may
wrongly assume that baclofen tolerance has occurred
and may not appreciate that the catheter or pump is
malfunctioning. In our case, systematic analysis of
the drug infusion device showed no programming
abnormality and it was not until contrast radiography
was used that the problem was identified. Pasquier 
et al recommend the use of computed tomography
with contrast to accurately locate the distal tip of the
catheter [19].
In conclusion, intrathecal baclofen pump delivery
systems provide a vehicle for the management of
medically intractable spasticity. However, malfunc-
tions in the intrathecal baclofen pump can be caused
by migration of the catheter tip or by other faults in
the catheter itself. To minimize the possibility of cath-
eter migration, adequate fixation to the supraspinous
fascia with both right-angled and straight anchors is
preferred.
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治療嚴重肌肉痙攣之脊膜內 Baclofen 注射幫浦術
後併發導管移位 — 病例報告
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我們報告一例脊膜內 baclofen 注射幫浦植入後併發導管移位的病案。在本病案中，
55 歲男性病患在頸部脊髓損傷合併四肢不完全癱瘓四年後，因嚴重的軀體與四肢痙攣
及僵直而接受脊膜內 baclofen 注射幫浦植入手術。在首次脊膜內注射幫浦植入手術 
12 個月後，病患又復發軀體緊繃與肌肉痙攣的症狀。以顯影劑注射於幫浦之側孔後，
以 X 光及電腦斷層照影檢查發現有顯影劑聚積於腰椎皮下區域，顯示導管系統移位進
入背部皮下區。因此，病患接受導管系統的重新置放手術。於重新置放導管之手術
中，我們特別注意避免留置於脊椎外的導管過長，並且以一個直角之導管固定器將導
管固定於脊椎上筋膜 (supraspinous fascia)。此外，導管之固定亦盡量使固定器至
導管進入脊椎上筋膜的距離縮短以避免因病人彎腰活動時導管外滑。病患於導管重新
置換後獲得肌肉痙攣僵直的改善，且於手術一年後的追蹤中接受每天 150 微克脊膜內 
baclofen 注射可獲得病情之穩定控制。因此，在本報告中，我們強調在裝置脊膜內注
射幫浦手術中幾項應注意的技術以固定幫浦的導管並防止導管移位及其相關之併發
症。
關鍵詞：baclofen，注射幫浦，脊膜內，肌肉痙攣，脊椎損傷，baclofen戒斷症候群
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